Skip to main content

Table 2 The expected values and 95% CrI of model outcomes over 10 years

From: Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US

Outcome Standard therapy Tiotropium Omalizumab
Cost (95% CrI) $38,432 ($32,075–$48,657) $41,535 ($35,034–$54,699) $217,847 ($214,477–$224,863)
QALYs (95% CrI) 6.79 (6.63–6.96) 6.88 (6.69–7.07) 7.17 (6.99–7.37)
Number of weeks with non-severe exacerbations (95% CrI) 20.04 (15.90–24.64) 14.53 (11.07–18.87) 9.92 (7.34–12.91)
Number of weeks with severe exacerbations without hospitalization (95% CrI) 11.39 (7.21–16.16) 8.22 (5.03–11.97) 7.15 (4.14–10.94)
Number of hospitalizations (95% CrI) 1.10 (0.45–2.19) 1.05 (0.31–2.46) 0.54 (0.14–1.48)
ICER
 Tiotropium versus standard therapy Reference $34,478/QALY
 Omalizumab versus tiotropium Reference $593,643/QALY
 Omalizumab versus standard therapy Reference $463,605/QALY
  1. CrI credible interval, QALY quality-adjusted life year, ICER Incremental cost-effectiveness ratio